proxyvotesnow.com

Home › Companies › PTC THERAPEUTICS INC. › 2024-2025

PTC THERAPEUTICS INC. 2024-2025 Proxy Voting Records

Compiled from SEC Form N-PX filings and PTC THERAPEUTICS INC.’s Form 8-K, filed 2025-06-17 (Item 5.07 on EDGAR). Page generated 02 October 2026.

  • 10Reported items
  • 259Asset managers
  • 1,706Fund votes
  • 2025-06-17Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore PTC THERAPEUTICS INC. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by PTC THERAPEUTICS INC.

These tallies are PTC THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2025-06-17 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

PTC THERAPEUTICS INC. — official shareholder meeting results, meeting held 2025-06-17
Ballot itemForAgainst AbstainWithheldBroker non-votesOutcome
Elect Director: Allan Jacobson, Ph.D. 60,386,986---- 2,122,2624,966,822 Majority: yes
Elect Director: David P. Southwell 59,200,375---- 3,308,8734,966,822 Majority: yes
Elect Director: Alethia Young 54,894,657---- 7,614,5914,966,822 Majority: yes

Source: PTC THERAPEUTICS INC., Form 8-K, filed with the SEC on 2025-06-17 — read the filing on EDGAR.

How asset managers voted at the PTC THERAPEUTICS INC. 2024-2025 meeting

Each item below shows how the 259 asset managers that disclosed a PTC THERAPEUTICS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of PTC THERAPEUTICS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. Approval on a non-binding, advisory basis, of the Company's named executive officer compensation as described in the proxy statement.

SECTION 14A SAY-ON-PAY VOTES

Meeting held 2025-06-17.

Combines 4 wordings of this item as funds reported it.

98% fund support · no official result

FOR 98%

The 246 asset managers below cast 98% of the shares they voted on this item FOR (68,155,132 for, 1,674,804 against).

FOR: 68,155,132 (97.6%)AGAINST: 1,674,804 (2.4%)ABSTAIN: 29,346 (0.0%)NOT VOTED: 60 (0.0%)
Largest asset managers voting on “Approval on a non-binding, advisory basis, of the Company's named executive officer compensation as described ” at PTC THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard11,757,3310 00For
RTW INVESTMENTS, LP7,546,4150 00For
BlackRock6,052,2040 00For
ARMISTICE CAPITAL, LLC5,332,4880 00For
Wellington4,974,2860 00For
Fidelity4,217,9410 00For
Janus Henderson2,943,5190 00For
State Street2,940,2860 00For
T. Rowe Price1,550,4120 00For
Charles Schwab1,345,7650 00For
FRANKLIN ADVISERS INC1,228,2070 00For
DRIEHAUS CAPITAL MANAGEMENT LLC1,059,9500 00For
Nuveen1,007,6100 00For
TIAA1,000,2970 00For
Camber Capital Management LP960,0000 00For
PICTET ASSET MANAGEMENT SA959,2360 00For
JANUS INVESTMENT FUND888,4200 00For
Northern Trust699,6730 00For
Hood River Capital Management LLC628,3870 00For
BNP Paribas Asset Management Holding S.A.0529,606 00Against
DE Shaw507,1010 00For
Invesco0504,482 00Against
Point72442,0860 00For
FRANKLIN STRATEGIC SERIES440,8110 00For
ROCKEFELLER FINANCIAL LLC421,7400 00For

Showing the 25 largest of 246 asset managers. See all 246 in the interactive database.

2. Election of Three Class III Directors: Allan Jacobson, Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2025-06-17.

Combines 6 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%
FOR: 60,386,986WITHHELD: 2,122,262

PTC THERAPEUTICS INC.’s own tally for this item (“Elect Director: Allan Jacobson, Ph.D.”): 60,386,986 for, 2,122,262 withheld, per its Form 8-K filed 2025-06-17 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 79,225,276 outstanding shares: 76% for, 3% withheld (79% of the company cast a for/withheld vote).

The 82 asset managers below cast 100% of the shares they voted on this item FOR (23,832,424 for, 0 against).

FOR 98%
FOR: 23,832,424 (97.9%)ABSTAIN: 514,776 (2.1%)
Largest asset managers voting on “Election of Three Class III Directors: Allan Jacobson, Ph.D.” at PTC THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard11,503,3930 00For
BlackRock3,017,3100 00For
Fidelity1,975,8150 00For
TIAA1,000,2970 00For
JANUS INVESTMENT FUND888,4200 00For
State Street721,9640 420For
Charles Schwab672,7530 00For
T. Rowe Price302,7090 321,3960Abstain
FRANKLIN STRATEGIC SERIES440,8110 00For
Manager Directed Portfolios372,3860 00For
Bridge Builder Trust321,5810 6,5380For
Hartford303,4680 00For
DRIEHAUS MUTUAL FUNDS225,4820 00For
Invesco212,9500 00For
Equitable121,1550 90,1700For
QUANTITATIVE MASTER SERIES LLC131,0120 00For
Brighthouse46,2210 49,1690Abstain
Lincoln Financial94,1840 00For
Goldman Sachs93,6450 00For
Prudential/PGIM88,0970 00For
Northwestern Mutual83,5640 00For
First Trust79,9690 00For
John Hancock78,3380 00For
Federated Hermes65,9860 00For
Global X58,0180 00For

Showing the 25 largest of 82 asset managers. See all 82 in the interactive database.

3. Election of Three Class III Directors: Alethia Young

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2025-06-17.

Combines 6 wordings of this item as funds reported it.

88% Majority: yes · of votes cast

FOR 88%12%
FOR: 54,894,657WITHHELD: 7,614,591

PTC THERAPEUTICS INC.’s own tally for this item (“Elect Director: Alethia Young”): 54,894,657 for, 7,614,591 withheld, per its Form 8-K filed 2025-06-17 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 79,225,276 outstanding shares: 69% for, 10% withheld (79% of the company cast a for/withheld vote).

The 81 asset managers below cast 100% of the shares they voted on this item FOR (20,709,034 for, 0 against).

FOR 85%ABSTAIN 15%
FOR: 20,709,034 (85.1%)ABSTAIN: 3,617,166 (14.9%)
Largest asset managers voting on “Election of Three Class III Directors: Alethia Young” at PTC THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard11,502,7570 6360For
BlackRock3,017,3100 00For
Fidelity1,975,8150 00For
TIAA00 1,000,2970Abstain
JANUS INVESTMENT FUND888,4200 00For
State Street722,0060 00For
Charles Schwab00 672,7530Abstain
T. Rowe Price00 624,1050Abstain
FRANKLIN STRATEGIC SERIES00 440,8110Abstain
Manager Directed Portfolios00 372,3860Abstain
Bridge Builder Trust328,1190 00For
Hartford303,4680 00For
DRIEHAUS MUTUAL FUNDS225,4820 00For
Invesco00 212,9500Abstain
Equitable121,1550 90,1700For
QUANTITATIVE MASTER SERIES LLC131,0120 00For
Brighthouse46,2210 49,1690Abstain
Lincoln Financial94,1840 00For
Goldman Sachs93,6450 00For
Prudential/PGIM85,1870 2,9100For
Northwestern Mutual83,5640 00For
First Trust79,9690 00For
John Hancock62,5850 15,7530For
Federated Hermes65,9860 00For
Global X00 58,0180Abstain

Showing the 25 largest of 81 asset managers. See all 81 in the interactive database.

4. Election of Three Class III Directors: David P. Southwell

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2025-06-17.

Combines 6 wordings of this item as funds reported it.

95% Majority: yes · of votes cast

FOR 95%
FOR: 59,200,375WITHHELD: 3,308,873

PTC THERAPEUTICS INC.’s own tally for this item (“Elect Director: David P. Southwell”): 59,200,375 for, 3,308,873 withheld, per its Form 8-K filed 2025-06-17 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 79,225,276 outstanding shares: 75% for, 4% withheld (79% of the company cast a for/withheld vote).

The 81 asset managers below cast 100% of the shares they voted on this item FOR (22,831,262 for, 0 against).

FOR 94%
FOR: 22,831,262 (93.9%)ABSTAIN: 1,494,938 (6.1%)
Largest asset managers voting on “Election of Three Class III Directors: David P. Southwell” at PTC THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard11,503,3930 00For
BlackRock3,017,3100 00For
Fidelity1,975,8150 00For
TIAA00 1,000,2970Abstain
JANUS INVESTMENT FUND888,4200 00For
State Street721,9640 420For
Charles Schwab672,7530 00For
T. Rowe Price302,7090 321,3960Abstain
FRANKLIN STRATEGIC SERIES440,8110 00For
Manager Directed Portfolios372,3860 00For
Bridge Builder Trust321,5810 6,5380For
Hartford303,4680 00For
DRIEHAUS MUTUAL FUNDS225,4820 00For
Invesco212,9500 00For
Equitable121,1550 90,1700For
QUANTITATIVE MASTER SERIES LLC131,0120 00For
Brighthouse46,2210 49,1690Abstain
Lincoln Financial94,1840 00For
Goldman Sachs93,6450 00For
Prudential/PGIM88,0970 00For
Northwestern Mutual83,5640 00For
First Trust79,9690 00For
John Hancock78,3380 00For
Federated Hermes65,9860 00For
Global X58,0180 00For

Showing the 25 largest of 81 asset managers. See all 81 in the interactive database.

5. RATIFICATION OF THE APPOINTMENT OF ERNST & YOUNG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2025.

AUDIT-RELATED

Meeting held 2025-06-17.

99.9% fund support · no official result

FOR 99.9%

The 79 asset managers below cast 99.9% of the shares they voted on this item FOR (24,333,952 for, 1,057 against).

FOR: 24,333,952 (100.0%)AGAINST: 1,057 (0.0%)ABSTAIN: 8,346 (0.0%)
Largest asset managers voting on “RATIFICATION OF THE APPOINTMENT OF ERNST & YOUNG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING” at PTC THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard11,503,3930 00For
BlackRock3,017,3100 00For
Fidelity1,975,8150 00For
TIAA1,000,2970 00For
JANUS INVESTMENT FUND888,4200 00For
State Street721,96442 00For
Charles Schwab672,7530 00For
T. Rowe Price624,1050 00For
FRANKLIN STRATEGIC SERIES440,8110 00For
Manager Directed Portfolios372,3860 00For
Bridge Builder Trust328,1190 00For
Hartford303,4680 00For
DRIEHAUS MUTUAL FUNDS225,4820 00For
Invesco212,9500 00For
Equitable211,3250 00For
QUANTITATIVE MASTER SERIES LLC131,0120 00For
Brighthouse87,0440 8,3460For
Lincoln Financial94,1840 00For
Goldman Sachs93,6450 00For
Prudential/PGIM88,0970 00For
Northwestern Mutual83,5640 00For
First Trust79,9690 00For
John Hancock78,3380 00For
Federated Hermes65,9860 00For
Global X58,0180 00For

Showing the 25 largest of 79 asset managers. See all 79 in the interactive database.

6. Advisory Vote to Ratify Named Executive Officers' Compensation

SECTION 14A SAY-ON-PAY VOTES

Meeting held 2025-06-17.

96% fund support · no official result

FOR 96%

The 7 asset managers below cast 96% of the shares they voted on this item FOR (621,269 for, 29,141 against).

FOR: 621,269 (95.5%)AGAINST: 29,141 (4.5%)
Largest asset managers voting on “Advisory Vote to Ratify Named Executive Officers' Compensation” at PTC THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
JPMorgan352,3940 00For
ADAGE CAPITAL PARTNERS GP, L.L.C.265,0000 00For
Desjardins Global Asset Management Inc.029,141 00Against
Virtus2,0610 00For
HC CAPITAL TRUST1,7550 00For
TD ASSET MANAGEMENT INC300 00For
UNIFIED SERIES TRUST290 00For

7. 14A Executive Compensation

SECTION 14A SAY-ON-PAY VOTES

Meeting held 2025-06-17.

100% fund support · no official result

FOR 100%

The 2 asset managers below cast 100% of the shares they voted on this item FOR (130 for, 0 against).

FOR: 130 (100.0%)
Largest asset managers voting on “14A Executive Compensation” at PTC THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Focus Partners Wealth1020 00For
Simplify Exchange Traded Funds280 00For

8. Ratify Appointment of Independent Auditors

AUDIT-RELATED

Meeting held 2025-06-17.

100% fund support · no official result

FOR 100%

The 2 asset managers below cast 100% of the shares they voted on this item FOR (2,089 for, 0 against).

FOR: 2,089 (100.0%)
Largest asset managers voting on “Ratify Appointment of Independent Auditors” at PTC THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Virtus2,0610 00For
Simplify Exchange Traded Funds280 00For

9. Ratify Ernst & Young LLP as Auditors

AUDIT-RELATED

Meeting held 2025-06-17.

100% fund support · no official result

FOR 100%

The 2 asset managers below cast 100% of the shares they voted on this item FOR (1,784 for, 0 against).

FOR: 1,784 (100.0%)
Largest asset managers voting on “Ratify Ernst & Young LLP as Auditors” at PTC THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
HC CAPITAL TRUST1,7550 00For
UNIFIED SERIES TRUST290 00For

10. Approval on a non-binding, advisory basis, of the Company's named executive officer compensation as described in the proxy statement.

SECTION 14A SAY-ON-PAY VOTES

Meeting held 2024-06-18 (outside the 2024-2025 season's 1 July to 30 June window; reported in this season's filings).

Combines 2 wordings of this item as funds reported it.

100% fund support · no official result

FOR 100%

The 2 asset managers below cast 100% of the shares they voted on this item FOR (778 for, 0 against).

FOR: 778 (100.0%)
Largest asset managers voting on “Approval on a non-binding, advisory basis, of the Company's named executive officer compensation as described ” at PTC THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
COLDSTREAM CAPITAL MANAGEMENT INC7780 00For
Echo45 Advisors LLC00 00--

Largest PTC THERAPEUTICS INC. shareholders voting in 2024-2025

Ranked by the number of PTC THERAPEUTICS INC. shares each manager voted on the most widely held ballot item of the 2024-2025 meeting, shown as a share of the 79,225,276 shares outstanding at the time of that meeting.

Top PTC THERAPEUTICS INC. shareholders by shares voted, 2024-2025
#Asset manager % of shares outstanding
1Vanguard 14.84%
2RTW INVESTMENTS, LP 9.53%
3BlackRock 7.64%
4ARMISTICE CAPITAL, LLC 6.73%
5Wellington 6.28%
6Fidelity 5.32%
7Janus Henderson 3.72%
8State Street 3.71%
9T. Rowe Price 1.96%
10Charles Schwab 1.70%

Reported PTC THERAPEUTICS INC. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

PTC THERAPEUTICS INC. beneficial owners on record for the 2024-2025 proxy season
Holder % outstanding Disclosure
Vanguard Group 10.86% 13F
BlackRock 9.81% 13F
RTW Investments, LP 9.37% DEF14A
JANUS HENDERSON GROUP PLC 9.08% 13G
Wellington Management 6.84% 13F
Vanguard Portfolio Management 6.15% 13G
Armistice Capital, LLC 4.14% 13G
The Toronto-Dominion Bank 3.82% 13G
State Street 3.10% 13F
FMR (Fidelity) 2.54% 13F

Percentages above are of 79,225,276 shares outstanding, as reported by PTC THERAPEUTICS INC. on its Form 10-Q dated 2025-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from PTC THERAPEUTICS INC.’s 10-Q dated 2025-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At PTC THERAPEUTICS INC.'s shareholder meeting held 2025-06-17, in the 2024-2025 proxy season, 259 asset managers reported how they voted in their SEC Form N-PX filings, covering 1,706 separate fund positions. Their filings are grouped here into 10 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. PTC THERAPEUTICS INC.'s own Form 8-K tally for this meeting is published below, but no row in it could be matched to the most widely held item, so this page states no certified outcome for that item. On that item — Approval on a non-binding, advisory basis, of the Company's named executive officer… — the reporting funds cast 98% of the shares they voted in favour (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). That is the aggregate of those managers' own N-PX disclosures, not the company's certified result, and the funds are a subset of all shareholders.

PTC THERAPEUTICS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.